4//SEC Filing
Nassif David W. 4
Accession 0001209191-18-049373
CIK 0001619087other
Filed
Sep 3, 8:00 PM ET
Accepted
Sep 4, 7:39 PM ET
Size
17.9 KB
Accession
0001209191-18-049373
Insider Transaction Report
Form 4
SteadyMed Ltd.STDY
Nassif David W.
Chief Financial Officer
Transactions
- Sale
Ordinary Shares
2018-08-30$4.46/sh−22,157$98,820→ 0 total - Other
Stock Option (Rt to Buy)
2018-08-30−3,100→ 0 totalExercise: $3.61Exp: 2019-07-19→ Ordinary Shares (3,100 underlying) - Other
Stock Option (Rt to Buy)
2018-08-30−159,642→ 0 totalExercise: $3.61Exp: 2020-05-01→ Ordinary Shares (159,642 underlying) - Other
Stock Option (Rt to Buy)
2018-08-30−40,000→ 0 totalExercise: $2.74Exp: 2026-06-17→ Ordinary Shares (20,000 underlying) - Other
Stock Option (Rt to Buy)
2018-08-30−51,832→ 0 totalExercise: $5.84Exp: 2022-01-25→ Ordinary Shares (51,832 underlying) - Other
Stock Option (Rt to Buy)
2018-08-30−15,987→ 0 totalExercise: $3.65Exp: 2027-12-28→ Ordinary Shares (15,987 underlying)
Footnotes (3)
- [F1]Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding restricted share unit was converted into the right to receive (1) a cash payment equal to (x) $4.46, multiplied by (y) the total number of shares subject to such restricted share unit and (2) a number of CVRs equal to the total number of shares subject to such restricted share unit.
- [F2]Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.
- [F3]Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time.
Documents
Issuer
SteadyMed Ltd.
CIK 0001619087
Entity typeother
Related Parties
1- filerCIK 0001636975
Filing Metadata
- Form type
- 4
- Filed
- Sep 3, 8:00 PM ET
- Accepted
- Sep 4, 7:39 PM ET
- Size
- 17.9 KB